Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diazoxide Suppression Test (DzST) Pilot & Feasibility Study
NCT06606327Phase 1Terminated
- Sponsor
- Columbia University
- Start
- Oct 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of diazoxide in hyperinsulinemia, sponsored by Columbia University. Primary endpoints: Fasting plasma glucose at 4 days and Fasting serum insulin at 4 days. Started Oct 2024; status: terminated.
02
Drugs
diazoxide
03
Conditions
hyperinsulinemia
Beyond the preview
Go deeper on NCT06606327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06606327.